Navigation Links
BioMarin to Present at the Bank of America Healthcare Conference
Date:5/7/2008

NOVATO, Calif., May 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Healthcare Conference in Las Vegas on Wednesday, May 14, 2008 at 1:20 p.m. PT.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors Media

Eugenia Shen Susan Berg

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

(415) 506-6570 (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.; Bank of America
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin Announces First Quarter 2008 Financial Results
2. BioMarin to Present at the Morgan Stanley Healthcare Conference
3. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
4. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
5. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
9. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
10. BioMarin to Present at the BioCentury NewsMakers Conference
11. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens ... for mesothelioma may be hampering the research that could lead to one good one. ... to read it now. , The team evaluated 98 mesothelioma patients ...
(Date:5/25/2016)... Connecticut (PRWEB) , ... May 25, 2016 , ... ... the U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug ... the company’s second orphan drug designation granted by the FDA. , Spinocerebellar ...
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® Media has ... 2017 and Beyond. The paper outlines the key trends that are creating both ... “We’ve witnessed a lot of highs and lows as the precision agriculture market ...
Breaking Biology Technology:
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/11/2016)... -- --> --> ... Market by Technology (Pattern Recognition), by Component (Hardware, Software, ... (On-Premises and Cloud), by Industry Vertical and by Region ... global market is expected to grow from USD 12.49 ... at a CAGR of 19.1%. , ...
Breaking Biology News(10 mins):